early fusion

The lack of gold standard methodology for synergy quantification of anticancer drugs warrants the consideration of different synergy metrics to develop efficient Artificial Intelligence-based predictive methods. Furthermore, neglecting combination sensitivity in synergy prediction may lead to biased synergistic combinations that are inefficient in conferring anticancer activity.